About Mitochondrial Medicine 2025 and Continuing Medical Education

On June 18-21, 2025, the United Mitochondrial Disease Foundation (UMDF) hosted Mitochondrial Medicine 2025 (MitoMed25) - This was a four-day scientific meeting conference directed toward the scientist and clinician interested in all aspects of mitochondrial science. The content of this educational program has been determined by rigorous assessment of educational needs and includes surveys, program feedback, expert faculty assessment, literature review, medical practice, and new medical knowledge.  

Select courses from MitoMed2025 have been made available for Continuing Medical Education credits as enduring material. The UMDF proudly hosts annual conferences, bringing together the mitochondrial medicine community. For more information about UMDF and the next UMDF Mito Med conference, visit www.umdfconference.org.


Continuing Medical Education Course Information

 

COURSE DESCRIPTION

The United Mitochondrial Disease Foundation and PeerPoint Medical Education Institute have joined efforts to sponsor and organize a CME-accredited activity. Mitochondrial diseases are more common than previously recognized and mitochondrial pathophysiology is now a recognized part of many disease processes, including heart disease, cancer, AIDS, diabetes and autism.  This live meeting is directed toward the scientist and clinician interested in obtaining a comprehensive update on mitochondrial medicine. The format will include didactic lectures from invited experts intermixed with rigorous discussion. There will be ample time for questions and answers throughout the program. 

 

TARGET AUDIENCE

Neurologists, Geneticists, Researchers/Scientists, Pediatrics, Internal Medicine, Nephrologists, Cardiologists, Endocrinologists, Genetic Counselors, Advanced Practice Nurses, Physicians Assistants, RNs, Occupational Therapy, Physical Therapy and Speech-Language Pathology, Nutritional Therapy, and Residents/Fellows/Students.

 

ACCREDITATION AND DESIGNATION STATEMENTS

Enduring Activity:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the United Mitochondrial Disease Foundation. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Live activity dates: June 18-21, 2025

Enduring activity dates: October 28, 2025 – October 28, 2028


LEARNING OBJECTIVES

Platform Session 2 - Inflammation and Metabolic

  • Analyze the role of mitochondrial dysfunction in the pathogenesis of diabetes and the development of in vivo assessment models for studying diabetes in primary mitochondrial diseases.
  • Examine the impact of mitochondrial dynamics and thermogenic fat activation on metabolic regulation and how obesity influences these processes.

Mitochondrial Medicine Society Clinical Platform Session

  • Recognize the signs and symptoms of acidosis in mitochondrial disease patients within the ICU setting and apply evidence-based strategies for effective management, including pharmacologic interventions and supportive care to improve patient outcomes.
  • Integrate advanced treatment protocols for stroke, seizure, and catastrophic complications in mitochondrial disease patients, emphasizing the need for early diagnosis, personalized interventions, and multidisciplinary care to reduce morbidity and enhance patient survival. 

Mito Med TK2d MasterClass for “Up and Coming” Clinicians

  • Enhance their ability to articulate the distinct clinical characteristics of Primary Mitochondrial Myopathies (PMM).
  • Improve skills in the ability to recognize, diagnose, and manage patients with TK2d.
  • Gain an understanding of how mitochondrial disease and TK2d affect various body systems.
  • Recognize the importance of a multidisciplinary team in the management of patient care.
  • Acknowledge the perspectives of patients and caregivers to provide more effective counseling to families.
  • Acquire knowledge of currently available treatments, emerging therapeutic options, and relevant clinical trials.